Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
    5.
    发明申请
    Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride 审中-公开
    含有盐酸二甲双胍的缓释药物组合物

    公开(公告)号:US20110195120A2

    公开(公告)日:2011-08-11

    申请号:US10272812

    申请日:2002-10-17

    IPC分类号: A61K9/22

    摘要: A monolithic sustained-release pharmaceutical composition comprising a therapeutically effective dose of metformin hydrochloride as an active substance and a hydrophobic polymer and/or other hydrophobic material, wherein the metformin hydrochloride is released no more than forty percent in gastric fluid having pH 1.2 and is released no less than ninety percent eight to ten hours after administration in simulated intestinal fluid (phosphate buffer) having pH 6.8, and wherein the metformin hydrochloride displays a peak plasma concentration, a systemic bioavailability over time, and a residual plasma concentration twenty-four hours after administration of an oral dosage form of the pharmaceutical composition, so that the metformin hydrochloride concentration remains therapeutically effective and once daily administration of the pharmaceutical composition is sufficient to be therapeutically effective throughout a day.

    摘要翻译: 一种整体缓释药物组合物,其包含治疗有效剂量的二甲双胍盐酸盐作为活性物质和疏水性聚合物和/或其它疏水材料,其中盐酸二甲双胍在pH 1.2的胃液中释放不超过百分之四十,并释放 在pH 6.8以上的模拟肠液(磷酸盐缓冲液)给药后8〜10小时不少于90%,其中盐酸二甲双胍显示峰值血药浓度,随时间推移的全身生物利用度和二十四小时后的残留血浆浓度 施用药物组合物的口服剂型,使得盐酸二甲双胍浓度保持治疗有效性,并且每天一次的药物组合物给药足以在一天内具有治疗有效性。